Head-To-Head Analysis: Global Wholehealth Partners (OTCMKTS:GWHP) & Insulet (NASDAQ:PODD)

Global Wholehealth Partners (OTCMKTS:GWHP) and Insulet (NASDAQ:PODD) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

Profitability

This table compares Global Wholehealth Partners and Insulet’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Global Wholehealth Partners	N/A	N/A	N/A
Insulet	10.44%	26.87%	12.01%

Valuation and Earnings

This table compares Global Wholehealth Partners and Insulet”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Global Wholehealth Partners	N/A	N/A	N/A	($0.05)	N/A
Insulet	$2.71 billion	3.73	$247.10 million	$4.30	33.96

Insulet has higher revenue and earnings than Global Wholehealth Partners. Global Wholehealth Partners is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Global Wholehealth Partners and Insulet, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Global Wholehealth Partners	0	0	0	0	0.00
Insulet	1	5	21	0	2.74

Insulet has a consensus price target of $252.48, indicating a potential upside of 72.92%. Given Insulet’s stronger consensus rating and higher probable upside, analysts plainly believe Insulet is more favorable than Global Wholehealth Partners.

Summary

Insulet beats Global Wholehealth Partners on 8 of the 8 factors compared between the two stocks.

About Global Wholehealth Partners

Global WholeHealth Partners Corporation develops and markets various in-vitro diagnostic (IVD) test kits in the United States. The company offers approximately 125 diagnostic tests kits for over-the-counter or consumer-use, as well as for point-of-care, which includes hospitals, physicians' offices, and medical clinics. It provides tests for various diseases, such as Ebola, zika, dengue, malaria, influenza, tuberculosis, coronaviruses, yellow fever, and other epidemic and vector-borne diseases. The company was incorporated in 2013 and is based in Newport Beach, California.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.